<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5801">
  <stage>Registered</stage>
  <submitdate>5/02/2016</submitdate>
  <approvaldate>5/02/2016</approvaldate>
  <nctid>NCT02677922</nctid>
  <trial_identification>
    <studytitle>A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)</studytitle>
    <scientifictitle>A Phase 1b/2 Open-label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AG-221-AML-005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Leukemia, Myeloid, Acute</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AG-120
Treatment: drugs - Azacitidine
Treatment: drugs - AG-221

Experimental: Oral AG-120 + Subcutaneous (SC) azacitidine - Subjects with an IDH1 mutation will receive AG-120 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.

Experimental: Oral AG-221 + Subcutaneous (SC) azacitidine - Subjects with an IDH2 mutation will receive AG-221 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.

Experimental: Subcutaneous (SC) azacitidine - Subjects with either an IDH1 or IDH2 mutation will receive azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.


Treatment: drugs: AG-120


Treatment: drugs: Azacitidine


Treatment: drugs: AG-221


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Dose limiting toxicities (DLTs)-Phase 1B - DLTs will be defined as any of the following events that commence within 28 days of the first dose of IP in a 28-day treatment cycle, constitute a change from baseline irrespective of outcome and are determined by the investigator to be related to treatment.</outcome>
      <timepoint>Up to approximately 7 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adverse Events (AEs) in Ph 1b - Number of participants with adverse events</outcome>
      <timepoint>Up to approximately 4 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics- Cmax - Maximum observed concentration in plasma</outcome>
      <timepoint>Up to approximately 7 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics- Tmax - Time to maximum concentration</outcome>
      <timepoint>Up to approximately 7 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics- AUC - Area under the plasma concentration-time curve</outcome>
      <timepoint>Up to approximately 7 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overall response rate (ORR) Ph 2 - Includes responses of Morphologic complete remission (CR), Morphologic complete remission with incomplete platelet recovery (CRp), morphologic leukemia-free state (MLFS), Morphologic complete remission with incomplete neutrophil recovery (CRi), and Partial remission (PR), according to modified International Working Group (IWG) Acute myeloid leukemia (AML) response criteria.</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate - Phase 1b (Ph 1b) - Rate of Morphologic complete remission (CR) + Morphologic complete remission with incomplete neutrophil recovery (CRi) + Morphologic complete remission with incomplete platelet recovery (CRp) + Morphologic leukemia-free state (MLFS) + Partial remission (PR) according to modified International Working Group (IWG) Acute myeloid leukemia (AML) response criteria</outcome>
      <timepoint>Up to approximately 13 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event-Free Survival - Phase 2 (Ph 2) - Time from randomization to documented morphologic relapse, progression according to modified International Working Group (IWG) Acute myeloid leukemia (AML) response criteria, or death from any cause, whichever occurs first.</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events (AEs) - Ph 2 - Number of participants with adverse events</outcome>
      <timepoint>Up to approximately 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complete remission rate - Ph 2 - Rate of morphologic complete remission (CR) according to modified International Working Group (IWG) Acute myeloid leukemia (AML) response criteria</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematologic improvement rate - Ph 2 - Rate of Hematologic improvement - neutrophil response (HI-N) + Hematologic improvement - platelet response (HI-P) + Hematologic improvement - erythroid response (HI-E) according to International Working Group (IWG) Myelodysplastic syndromes (MDS) Hematologic improvement(HI) criteria</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response - Ph 2 - Time from the first documented MLFS/CR/CRi/CRp/PR to documented morphologic relapse, progression according to modified IWG AML response criteria, or death due to any cause, whichever occurs first</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Ph 2 - Time from randomization to death due to any cause</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>One-year survival- Ph 2 - The probability of survival at 1 year from randomization</outcome>
      <timepoint>Up to approximately 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics- Cmax - Ph 2 - Maximum observed concentration in plasma</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics- Tmax - Ph 2 - Time to maximum concentration</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics- AUC - Ph 2 - Area under the plasma concentration-time curve</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>EORTC QLQ-C30 - European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire - Ph 2 - Is a validated quality-of-life measure applicable to subjects with any cancer diagnosis. It is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>EQ-5D-5L Health Questionnaire - Ph 2 - Is a standardized instrument for use as a measure of health outcome. It provides a simple descriptive profile and a single index value for health status, and is applicable to a wide range of health conditions and treatments</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate - Phase 1b (Ph 2) - Rate of Morphologic complete remission (CR) + Morphologic complete remission with incomplete neutrophil recovery (CRi) + Morphologic complete remission with incomplete platelet recovery (CRp) + Morphologic leukemia-free state (MLFS) +Partial remission (PR) according to modified International Working Group (IWG) Acute myeloid leukemia (AML) response criteria</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Response - Phase 2 - Time from first dose of study drug to first documented Morphologic complete remission (CR)/ Morphologic complete remission with incomplete neutrophil recovery (CRi)/ Morphologic complete remission with incomplete platelet recovery (CRp)/ Morphologic leukemia-free state (MLFS)/ Partial remission (PR) according to modified International Working Group (IWG) Acute myeloid leukemia (AML) response criteria</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects must satisfy the following criteria to be enrolled in the study:

          1. Subject is = 18 years of age the time of signing the informed consent form (ICF).

          2. Subject must understand and voluntarily sign an ICF prior to any study-related
             assessments/procedures being conducted.

          3. Subject is willing and able to adhere to the study visit schedule and other protocol
             requirements.

          4. Subject has newly diagnosed, primary (ie, de novo) or secondary (progression of MDS or
             myeloproliferative neoplasms [MPN], or therapy-related) AML according to the WHO
             classification with = 20% leukemic blasts in the bone marrow: -Have an Isocitrate
             dehydrogenase 1 (IDH1) or Isocitrate dehydrogenase 2 (IDH2) gene mutation (R132, R140,
             or R172)

               -  IDH mutational status will be assessed locally; for sites without local testing
                  capabilities, a referral lab will be identified.

                    -  By the investigator's assessment who are not candidates to receive intensive
                       Inductive chemotherapy (IC).

          5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or
             2.

          6. Subject has adequate organ function defined as:

               -  Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase
                  (AST/SGOT) and alanine aminotransferase (ALT/SGPT) = 3 x ULN, unless considered
                  due to leukemic organ involvement.

               -  Serum total bilirubin &lt; 1.5 x ULN. Higher levels are acceptable if these can be
                  attributed to ineffective erythropoiesis, 3 times the upper limit of normal for
                  Gilbert's syndrome (eg, a gene mutation in UGT1A1), or leukemic organ
                  involvement.

               -  Serum creatinine &lt; 2 x ULN or creatinine clearance &gt; 30 mL/min based on the
                  Modification of Diet in Renal Disease (MDRD) glomerular filtration rate (GFR):

             GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if
             African American)

          7. Agree to serial bone marrow aspirate/biopsies.

          8. Females of childbearing potential (FCBP)* may participate, providing they meet the
             following conditions:

               -  Agree to practice true abstinence ** from sexual intercourse or to use highly
                  effective contraceptive methods (eg, combined [containing estrogen and
                  progestogen] or progestogen only associated with inhibition of ovulation, oral,
                  injectable, intravaginal, patch, or implantable hormonal contraceptive; bilateral
                  tubal occlusion; intra-uterine device; intrauterine hormone-releasing system; or
                  male partner sterilization [note that a vasectomized partner is a highly
                  effective birth control method provided that partner is the sole sexual partner
                  of the FCBP trial participant and that a vasectomized partner has received
                  medical assessment of the surgical success]) at screening and throughout the
                  study, and for at least 4 months following the last study treatment; and

               -  Have a negative serum ß-subunit of human chorionic gonadotropin (ß-hCG) pregnancy
                  test (sensitivity of at least 25 mIU/mL) at screening; and

               -  Have a negative serum or urine (investigator's discretion under local
                  regulations) ß-hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72
                  hours prior to the start of study treatment in the Treatment Period (note that
                  the screening serum pregnancy test can be used as the test prior to the start of
                  study treatment in the Treatment Period if it is performed within the 72-hour
                  timeframe).

          9. Male subjects must agree to practice true abstinence from sexual intercourse or agree
             to the use of highly effective contraceptive methods (as described above) with
             non-pregnant female partners of child bearing potential at screening and throughout
             the course of the study and should avoid conception with their partners during the
             course of the study and for at least 4 months following the last study treatment (6
             months following last dose of azacitidine in Canada). Furthermore, the male subject
             must agree to use a condom while treated with azacitidine and for at least 4 months
             following the last azacitidine dose.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- The presence of any of the following will exclude a subject from enrollment:

          1. Subject is suspected or proven to have acute promyelocytic leukemia based on
             morphology, immunophenotype, molecular assay, or karyotype.

          2. Subject has AML secondary to chronic myelogenous leukemia (CML).

          3. Subject has received a targeted agent against an Isocitrate dehydrogenase 1 (IDH1) or
             Isocitrate dehydrogenase 2 (IDH2) mutation.

          4. Subject has received prior systemic anticancer therapy, HSCT, or radiotherapy for AML.

             Note: Hydroxyurea is allowed prior to enrollment for the control of peripheral
             leukemic blasts in subjects with leukocytosis. (however, hydroxyurea should not be
             given within 72 hours prior to and after administration of azacitidine). For subjects
             with secondary AML (eg, MDS or MPN) treatment for prior cancer is not exclusionary;
             full treatment information will be collected within the CRF. The use of all trans
             retinoic acid (ATRA) for suspected APL is not exclusionary provided it is discontinued
             prior to initiation of treatment in the protocol.

          5. Subject has received more than 1 cycle of prior treatment with azacitidine, or subject
             has received any prior treatment with decitabine for Myelodysplastic syndromes (MDS).

             - Clarification: Subjects with newly diagnosed Acute myeloid leukemia (AML) who are
             currently receiving their 1st cycle of azacitidine (7 days) can be screened for the
             study. On study, Cycle 1 must be started at 28 days (+/- 3 days) after initiation of
             the pre-study azacitidine.

          6. Subject has or is suspected of having central nervous system (CNS) leukemia.
             Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is
             suspected during screening.

          7. Subject has immediate life-threatening, severe complications of leukemia such as
             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated
             intravascular coagulation.

          8. Subject has significant active cardiac disease within 6 months prior to the start of
             study treatment, including New York Heart Association (NYHA) class III or IV
             congestive heart failure; acute coronary syndrome (ACS); and/or stroke; or left
             ventricular ejection fraction (LVEF) &lt; 40% by echocardiogram (ECHO) or multi-gated
             acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment.

          9. Subject has prior history of malignancy, other than MDS, Myeloproliferative neoplasm
             (MPN), or AML, unless the subject has been free of the disease for = 1 year prior to
             the start of study treatment. However, subjects with the following history/concurrent
             conditions are allowed:

               -  Basal or squamous cell carcinoma of the skin

               -  Carcinoma in situ of the cervix

               -  Carcinoma in situ of the breast

               -  Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,
                  node, metastasis clinical staging system)

         10. Subject is known seropositive for or has active viral infection with human
             immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or
             hepatitis C virus (HCV)

         11. Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other
             conditions that limit the ingestion or gastrointestinal absorption of drugs
             administered orally

         12. Subject has uncontrolled hypertension (systolic blood pressure [BP] &gt; 180 mmHg or
             diastolic BP &gt; 100 mmHg)

         13. Subject is taking the following sensitive CYP substrate medications that have a narrow
             therapeutic range are excluded from the study unless the subject can be transferred to
             other medications at least 5 half-lives prior to the start of study treatment:
             phenytoin (CYP2C9), S-mephenytoin (CYP2C19), thioridazine (CYP2D6), theophylline, and
             tizanidine (CYP1A2).

         14. Subject is taking the breast cancer resistance protein (BCRP) transporter-sensitive
             substrate rosuvastatin; subject should be excluded from the study unless he/she can be
             transferred to other medications at least 5 half-lives prior to the start of study
             treatment.

         15. Subject has active uncontrolled systemic fungal, bacterial, or viral infection
             (defined as ongoing signs/symptoms related to the infection without improvement
             despite appropriate antibiotics, antiviral therapy, and/or other treatment).

         16. Subject has known or suspected hypersensitivity to any of the components of study
             therapy.

         17. Subject is taking medications that are known to prolong the QT interval unless he/she
             can be transferred to other medications within = 5 half-lives prior to the start of
             study treatment.

         18. Subject has Heart rate-corrected QT (QTc) interval (ie, Fridericia's correction
             [QTcF]) = 450 ms or other factors that increase the risk of QT prolongation or
             arrhythmic events (eg, heart failure, hypokalemia, family history of long QT interval
             syndrome) at screening.

         19. Female subject who is pregnant or lactating.

         20. Subject has any significant medical condition, laboratory abnormality, or psychiatric
             illness that would prevent the subject from participating in the study.

         21. Subject has any condition, including the presence of laboratory abnormalities that
             places the subject at unacceptable risk if he/she were to participate in the study.

         22. Subject has any condition that confounds the ability to interpret data from the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>3/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>127</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Parkville Cancer Clinical Trials Unit - Melbourne</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>SA 5000 - Adelaide</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3141 - Melbourne</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Chambray les Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Düsseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Orbassano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pesaro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Breña Alta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Caceres</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Headington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sidcup</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Celgene</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase 1b/2 study is an open-label, randomized, multicenter trial to evaluate the safety
      and efficacy of oral AG-120 + Subcutaneous (SC) azacitidine and oral AG-221 + SC azacitidine
      in subjects with newly diagnosed AML with an IDH1 or an IDH2 mutation, respectively. The
      study population consists of subjects who are not candidates to receive intensive Inductive
      chemotherapy (IC). The study comprises a Phase 1b dose-finding and AG-120 expansion stage and
      a Phase 2 randomized stage.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02677922</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ira Gupta, MD</name>
      <address>Celgene Corporation</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Associate Director Clinical Trial Disclosure</name>
      <address />
      <phone>1-888-260-1599</phone>
      <fax />
      <email>clinicaltrialdisclosure@celgene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>